UIC
FLXN

Uniplan Investment Counsel’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Uniplan Investment Counsel’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-72,072
Closed -$750K – 132
2020
Q3 		$750K Buy
72,072
+2,361
+3% +$28.9K 0.05% 120
2020
Q2 		$916K Sell
69,711
-1,864
-3% -$19.3K 0.06% 116
2020
Q1 		$563K Buy
71,575
+10,126
+16% +$153K 0.04% 119
2019
Q4 		$1.27M Buy
61,449
+974
+2% +$16.4K 0.08% 116
2019
Q3 		$828K Sell
60,475
-3,973
-6% -$47.1K 0.05% 115
2019
Q2 		$792K Sell
64,448
-15,900
-20% -$183K 0.05% 123
2019
Q1 		$1M Sell
80,348
-12,529
-13% -$167K 0.06% 117
2018
Q4 		$1.05M Sell
92,877
-3,088
-3% -$48.4K 0.07% 111
2018
Q3 		$1.79M Sell
95,965
-13,038
-12% -$300K 0.1% 106
2018
Q2 		$2.82M Sell
109,003
-19,921
-15% -$517K 0.14% 100
2018
Q1 		$2.89M Buy
128,924
+1,820
+1% +$44.4K 0.14% 111
2017
Q4 		$3.18M Buy
127,104
+3,200
+3% +$78.4K 0.13% 113
2017
Q3 		$3M Buy
+123,904
New +$2.91M 0.13% 110

Other funds holding FLXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Uniplan Investment Counsel's FLXN Position: Q4 2020 in Review

Uniplan Investment Counsel sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2020, closing a stake of 72,072 shares — an estimated $750K sold.

Uniplan Investment Counsel first reported a position in FLXN in Q3 2017 and held it in 13 quarters. The position peaked at $3.18M in Q4 2017. 141 funds tracked by Wall St. Rank hold FLXN as of Q4 2020.

  • Uniplan Investment Counsel reported no remaining Flexion Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Uniplan Investment Counsel sold 72,072 Flexion Therapeutics, Inc. shares in Q4 2020, an estimated $750K.
  • Uniplan Investment Counsel first reported a position in Flexion Therapeutics, Inc. in Q3 2017 and held it in 13 quarters.
  • Uniplan Investment Counsel's Flexion Therapeutics, Inc. position peaked at $3.18M in Q4 2017.
  • 141 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2020.

Based on Uniplan Investment Counsel's 13F filing for Q4 2020, filed 12 Feb 2021.